Related Experiment Videos
Polymer heart valves
J A Hyde1, J A Chinn, R E Phillips
1Department of Cardiothoracic Surgery, Queen Elizabeth Hospital, Birmingham, UK.
The Journal of Heart Valve Disease
|July 10, 1999
Summary
Researchers are developing advanced polymer heart valves to overcome limitations of current prostheses. Surface modification shows promise in preventing calcification and thrombus, potentially offering a new clinical option.
Area of Science:
- Biomaterials Science
- Cardiovascular Surgery
- Polymer Engineering
Background:
- Current heart valve prostheses, including bioprostheses and mechanical valves, have limitations such as calcification, premature failure, and thrombogenicity.
- The development of artificial heart valves aims to create a safe, durable, and effective alternative to address these shortcomings.
Purpose of the Study:
- To review the historical development of polymer heart valves.
- To discuss the current state of research and evaluation of polymer valve technology.
- To highlight advancements in materials and design for improved prosthetic valves.
Main Methods:
- Review of historical data and research literature on polymer valve development.
- Analysis of in vitro and in vivo testing results for various polymer valve designs.
- Exploration of surface modification techniques for enhanced biocompatibility.
Main Results:
- Significant progress has been made in polymer valve design and materials, with extensive in vitro and in vivo testing.
- While design challenges have been largely overcome, calcification remains a concern, though less severe than with bioprostheses.
- Emerging surface modification technologies show promising early in vivo results for eliminating thrombus and calcification.
Conclusions:
- Polymer heart valves have faced developmental hurdles but are progressing towards clinical viability.
- Surface modification techniques represent a key advancement in addressing critical issues like calcification and thrombogenicity.
- An effective and safe polymer valve is anticipated to become a significant third clinical option in heart valve replacement therapy.